Prognostic significance of systemic immune inflammation indices and prognostic nutritional index before CDK4/6 inhibitor therapy in hormone receptor positive, HER2 negative metastatic breast cancer patients
Öz
Purpose: As systemic inflammatory indices and prognostic nutritional index are associated with poor prognosis in many tumor types, the goal of the present study was to ascertain their effect along with the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, C-reactive protein/albumin ratio, and systemic inflammatory response index on the progression-free survival (PFS) and overall survival (OS) of hormone receptor-positive HER2-negative (HR+/HER2−) metastatic breast cancer patients before CDK4/6 inhibitor treatment.
Materials and methods: The medical records of 79 patients with HR+/HER2− metastatic breast cancer who presented at the Medical Oncology Outpatient Clinic between January 2018 and May 2022 were retrospectively analyzed to gather relevant data measured before CDK4/6 inhibitor treatment in order to establish the effect of key markers on their PFS and OS.
Results: The median age of the participating patients, 70 (88.6%) of whom were postmenopausal, was 53 years (range 26-80 years). While 68 patients (86.1%) had a 0 performance score, 10 (12.7%) developed metastases during adjuvant endocrine therapy. Factors affecting PFS were age <50 (p=0.061), metastasis development during adjuvant endocrine therapy (p=0.09) and C-reactive protein/albumin ratio (p=0.019), while OS was primarily influenced by age <50 (p=0.069) and metastasis development during adjuvant endocrine therapy (p=0.012).
Conclusion: In the examined HR+/HER2− metastatic breast cancer patients, systemic inflammatory indices and prognostic nutritional index before CDK4/6 inhibitor treatment affected PFS. In addition, metastasis development during adjuvant endocrine therapy, progesterone receptor percentage, and age below 50 years emerged as prognostic factors for shorter overall survival.
Anahtar Kelimeler
HR+/HER2− metastatic breast cancer, CDK4/6 inhibitors, systemic inflammatory indices, prognostic nutritional index, PFS
Kaynakça
- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249. https://doi.org/10.3322/caac.21660
- 2. Harbeck N, Gnant M. Breast cancer. Lancet 2017;389:1134-1150. https://doi.org/10.1016/S0140-6736(16)31891-8
- 3. Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:691-722. https://doi.org/10.6004/jnccn.2022.0030
- 4. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32:1475-1495. https://doi.org/10.1016/j.annonc.2021.09.019
- 5. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-1987. https://doi.org/10.1158/1078-0432.CCR-09-1823
- 6. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783. https://doi.org/10.1200/JCO.2005.03.768
- 7. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 2018;29:1541-1547. https://doi.org/10.1093/annonc/mdy155
- 8. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-439. https://doi.org/10.1016/S1470-2045(15)00613-0
- 9. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638-3646. https://doi.org/10.1200/JCO.2017.75.6155 10. Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells 2020;9:855. https://doi.org/10.3390/cells9040855
- 11. Hu B, Yang XR, Xu Y, et al. Systemic Immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212-6222. https://doi.org/10.1158/1078-0432.CCR-14-0442
